Diligence memo · auto-generated · as of July 2, 2026
Averna Therapeutics Inc.
Averna Therapeutics Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Averna Therapeutics Inc. operates in Pharma, based in WATERTOWN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Averna Therapeutics Inc. has raised $85M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $85M on 2024-04-08.
Most recent recorded round closed around 2024-04-08.
Valuation (modeled)modeled
Provath models Averna Therapeutics Inc. at approximately $806M (range $276M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.27× the median modeled value of Series C Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (127% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 89% of Pharma peers (310 compared).
Modeled value ranks above 88% of those peers.
Closest niche peers: Circle Pharma, Inc., Soleno Therapeutics Inc, Progentos Therapeutics, Inc., Intrinsic Therapeutics Inc, Digital Therapeutics, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.